Relcobatinib Paper Maps Selective BCR ABL1 Binding

Company Enliven Therapeutics Event Type Peer-reviewed publication (Leukemia) Modality Small molecule Asset Relcobatinib (ELVN-001) Target BCR::ABL1 (active site) Disease Area Chronic myeloid leukemia Summary Previously missed November 3 online Leukemia article describes the structure and preclinical selectivity of relcobatinib (ELVN-001), an active-site BCR::ABL1 inhibitor already…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *